NovoCure (NVCR) Projected to Post Quarterly Earnings on Thursday

NovoCure (NASDAQ:NVCR) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect NovoCure to post earnings of ($0.40) per share and revenue of $174.3980 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

NovoCure Stock Performance

Shares of NVCR opened at $11.40 on Thursday. The company has a quick ratio of 1.50, a current ratio of 1.55 and a debt-to-equity ratio of 0.57. NovoCure has a 52-week low of $9.82 and a 52-week high of $22.30. The company has a 50-day simple moving average of $12.79 and a 200-day simple moving average of $12.60. The company has a market capitalization of $1.28 billion, a PE ratio of -7.08 and a beta of 0.73.

Analyst Upgrades and Downgrades

NVCR has been the subject of a number of research analyst reports. JPMorgan Chase & Co. dropped their target price on shares of NovoCure from $25.00 to $23.00 and set a “neutral” rating for the company in a report on Monday, October 27th. Wedbush reaffirmed a “neutral” rating and issued a $18.00 price objective on shares of NovoCure in a research note on Thursday, January 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NovoCure in a report on Thursday, January 22nd. Evercore set a $20.00 target price on NovoCure in a report on Monday, January 5th. Finally, HC Wainwright lifted their price target on NovoCure from $39.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $26.64.

Institutional Trading of NovoCure

Several institutional investors and hedge funds have recently made changes to their positions in NVCR. Mercer Global Advisors Inc. ADV boosted its stake in shares of NovoCure by 14.5% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 32,660 shares of the medical equipment provider’s stock valued at $422,000 after acquiring an additional 4,124 shares during the last quarter. Empowered Funds LLC acquired a new stake in shares of NovoCure during the 4th quarter worth about $33,000. XTX Topco Ltd boosted its stake in shares of NovoCure by 159.2% during the 4th quarter. XTX Topco Ltd now owns 58,795 shares of the medical equipment provider’s stock worth $760,000 after purchasing an additional 36,111 shares during the last quarter. Vestal Point Capital LP grew its holdings in shares of NovoCure by 31.3% during the fourth quarter. Vestal Point Capital LP now owns 525,000 shares of the medical equipment provider’s stock worth $6,788,000 after buying an additional 125,000 shares in the last quarter. Finally, Susquehanna Portfolio Strategies LLC raised its position in shares of NovoCure by 981.7% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 289,359 shares of the medical equipment provider’s stock valued at $3,741,000 after buying an additional 262,609 shares during the last quarter. 84.61% of the stock is currently owned by hedge funds and other institutional investors.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.